Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.74 |
| ▸ | PNP | P00491 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 2/20 | 0.55 |
| ▸ | CD99 | P14209 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970868 | 0.89 | LMNA (0.58) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL2789344 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL21303677 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL3775 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL4527409 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL11949489 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL1697053 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL11948325 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL7969581 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL17367349 | 0.85 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757380-B2 | Methods for treating neoplasia with combination of chemotherapeutic agents and radiation | SOUTHERN RESEARCH INSTITUTE (US) | 2017-09-12 | — | — | US | disclosed |
| EP-2136631-B1 | METHODS FOR TREATING NEOPLASIA WITH COMBINATION OF CHEMOTHERAPEUTIC AGENTS AND RADIATION | SOUTHERN RES INST (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2136631-A1 | METHODS FOR TREATING NEOPLASIA WITH COMBINATION OF CHEMOTHERAPEUTIC AGENTS AND RADIATION | Southern Research Institute (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080262003-A1 | METHODS FOR TREATING NEOPLASIA WITH COMBINATION OF CHEMOTHERAPEUTIC AGENTS AND RADIATION | SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZATION AND INTELLECTUAL PROP (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008128170-A1 | METHODS FOR TREATING NEOPLASIA WITH COMBINATION OF CHEMOTHERAPEUTIC AGENTS AND RADIATION | SOUTHERN RESEARCH INSTITUTE (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262003-A1 | METHODS FOR TREATING NEOPLASIA WITH COMBINATION OF CHEMOTHERAPEUTIC AGENTS AND RADIATION | XPA, BRCA1, RAD51 | PDE4D 4527/4885PDE3A 3559/4885PNP 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.